Ryosuke Fujikane

Ryosuke Fujikane

Auto-generated profile, based on publicly available information

Ryosuke Fujikane

Department of Physiological Science and Molecular Biology, Fukuoka Dental College, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
AFAya Fujikane
Aya Fujikane
ASAtsuhiko Sakamoto
Atsuhiko Sakamoto
RFRyosuke Fujikane
Ryosuke Fujikane
ANAkinori Nishi
Akinori Nishi
YIYoshizumi Ishino
Yoshizumi Ishino
SNShigeki Nabeshima
Shigeki Nabeshima
Although respiratory syncytial virus (RSV) is a major cause of respiratory tract infection in children, no effective therapies are available. Recently, RSV G, the attachment glycoprotein, has become a major focus in the development of therapeutic strategies against RSV infection. Treatment of RSV-infected cultured cells with maoto, a traditional herbal medicine for acute febrile diseases, significantly reduced the viral RNA and titers. RSV attachment to the cell surface was inhibited both in the presence of maoto and when RSV particles were pre-treated with maoto. We demonstrated that maoto components, Ephedrae Herba (EH) and Cinnamomi Cortex (CC), specifically interacted with the central conserved domain (CCD) of G protein, and also found that this interaction blocked viral attachment to the cellular receptor CX3CR1. Genetic mutation of CX3C motif on the CCD, the epitope for CX3CR1, decreased the binding capacity to EH and CC, suggesting that CX3C motif was the target for EH and CC. Finally, oral administration of maoto for five days to RSV-infected mice significantly reduced the lung viral titers. These experiments clearly showed the anti-RSV activity of EH and CC mixed in maoto. Taken together, this study provides insights for the rational design of therapies against RSV infection.

2 June 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YUYuka Uechi
Yuka Uechi
RFRyosuke Fujikane
Ryosuke Fujikane
SMSho Morita
Sho Morita
STSachio Tamaoki
Sachio Tamaoki
MHMasumi Hidaka
Masumi Hidaka

9 April 2022 in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
Verified
Journal Article
Closed access
ATArato Takedachi
Arato Takedachi
EMErina Matsuishi
Erina Matsuishi
SMShouji Mizusaki
Shouji Mizusaki
TNTomoki Nagasawa
Tomoki Nagasawa
RFRyosuke Fujikane
Ryosuke Fujikane
IKIsao Kuraoka
Isao Kuraoka

14 June 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
SMSho Morita
Sho Morita
RFRyosuke Fujikane
Ryosuke Fujikane
YUYuka Uechi
Yuka Uechi
TMTakashi Matsuura
Takashi Matsuura
MHMasumi Hidaka
Masumi Hidaka

10 February 2021 in Oral Science International
Verified
Journal Article
Closed access
PDF file
YOYuko Obayashi
Yuko Obayashi
RFRyosuke Fujikane
Ryosuke Fujikane
SMShou Morita
Shou Morita
YUYuka Uechi
Yuka Uechi
AHAkimitsu Hiraki
Akimitsu Hiraki
MHMasumi Hidaka
Masumi Hidaka

3 June 2025 in Microbiology Spectrum
Verified
Journal Article
Open access
AFAya Fujikane
Aya Fujikane
RFRyosuke Fujikane
Ryosuke Fujikane
YSYusuke Sechi
Yusuke Sechi
ANAkinori Nishi
Akinori Nishi
YIYoshizumi Ishino
Yoshizumi Ishino
SNShigeki Nabeshima
Shigeki Nabeshima
Maoto, a traditional herbal medicine widely prescribed in Japan, has been shown to be effective in the treatment of influenza virus infection, but the mechanisms of its antiviral action remain unclear. We previously demonstrated that maoto binds to respiratory syncytial virus (RSV) spike proteins, thereby inhibiting their entry into host cells. In this report, a similar experiment was done to determine if maoto and its components have an anti-infective effect on the influenza virus. Our results indicate that maoto binds to the hemagglutinin (HA) spike protein, inhibiting virus entry into host cells in a manner analogous to its antiviral effect on RSV. This hemagglutinin-binding effect was observed across influenza A(H1N1), A(H3N2), and B viruses, highlighting the broad-spectrum inhibitory potential of maoto against diverse viral strains. Furthermore, maoto, internalized by cells along with the influenza virus, binds to a cap-dependent endonuclease (polymerase acidic [PA] protein) that is crucial for viral replication and inhibits its nuclease activity. Among maoto’s constituent crude drugs, Ephedrae Herba (EH) and Cinnamomi Cortex (CC) were found to bind to both hemagglutinin and PA, indicating that they are responsible for the anti-infective effect of maoto. Maoto is distinctive in its multiple points of antiviral action, exhibiting a broad spectrum of antiviral properties, which makes it a versatile therapeutic agent against various viral mutations. IMPORTANCE: The influenza virus is a formidable pathogen responsible for global pandemics that claim over 300,000 lives annually. Employing an ingenious evolutionary strategy, this virus undergoes constant mutation, deftly evading the action of therapeutic agents and sustaining its relentless impact. Maoto, a traditional herbal medicine, has long been known for its efficacy against viral infections and is frequently prescribed in Japan for the treatment of influenza; however, the precise mechanisms of its action remain unclear. Our study was done to elucidate the antiviral mechanisms of maoto against the influenza virus, presenting data that supports its unique potential as a therapeutic agent capable of flexibly adapting to mutations of the influenza virus. These findings pave the way for the development of new drugs and the expansion of therapeutic options.